Comparative Pharmacology
Head-to-head clinical analysis: NOGENIC HC versus ORTHO CYCLEN 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOGENIC HC versus ORTHO CYCLEN 28.
NOGENIC HC vs ORTHO CYCLEN-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NOGENIC HC contains hydrocortisone, a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription and reducing inflammation, immune responses, and cytokine production.
Combination oral contraceptive containing ethinyl estradiol and norgestimate. The primary mechanism is inhibition of gonadotropin secretion (FSH and LH) via negative feedback on the hypothalamic-pituitary axis, thereby suppressing ovulation. Additional effects include thickening of cervical mucus (impedes sperm penetration) and alterations in the endometrium (reduces implantation likelihood).
NOGENIC HC is not a recognized drug. Please verify the name. No dosing information available.
One tablet (0.18 mg norgestimate/0.035 mg ethinyl estradiol) orally once daily for 28 days, first tablet on day 1 of menstrual cycle with 7 placebo tablets in last 7 days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours. In patients with hepatic impairment, half-life may be prolonged up to 24 hours; no dose adjustment required for renal impairment.
Ethinyl estradiol: 13-27 hours; Norelgestromin (active metabolite of norgestimate): 28-52 hours. Terminal half-lives support once-daily dosing.
Primarily hepatic metabolism; biliary excretion accounts for approximately 80%; renal elimination of inactive metabolites less than 5% as unchanged drug.
Renal (60-70% as metabolites, ~20% unchanged), Fecal (30-40% as metabolites); primarily conjugated metabolites of ethinyl estradiol and norgestimate.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive